Staging systems for hepatocellular carcinoma: Current status and future perspectives

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 3

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Mar 27, 2015; 7(3): 406-424
Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.406

Table 4 Chines University Prognostic Index

Variable	Weight
TNM stage
Iand II	-3
IIIa and IIIb	-1
IVa and IVb	0
Asymptomatic disease on presentation	-4
Presence of ascites	3
AFP ≥ 500 ng/mL	2
Total bilirubin (μmol/L)
< 34	0
34-51	3
≥ 52	4
ALP ≥ 200 (IU/L)	3

≤ 1: Low risk; 2-7: Intermediate risk; ≥ 8: High risk. AFP: Alpha-fetoprotein; ALP: Alkaline phosphatase.

Citation: Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol 2015; 7(3): 406-424
URL: https://www.wjgnet.com/1948-5182/full/v7/i3/406.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i3.406

Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol 2015; 7(3): 406-424 [PMID: 25848467 DOI: 10.4254/wjh.v7.i3.406]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.